Toxicity study and blood pressure–lowering efficacy of whey protein concentrate hydrolysate in rat models, plus peptide characterization

Toxicity study and blood pressure–lowering efficacy of whey protein concentrate hydrolysate in rat models, plus peptide characterization

We evaluated the acute (single-dose) and subacute (repeated-dose) oral toxicity of alcalase-hydrolyzed whey protein concentrate. Our acute study revealed no death or treatment-related complications, and the median lethal dose of whey protein concentrate hydrolysate was >2,500 mg/kg. In the subacu...

Full description

Bibliographic Details
Main Authors: Auwal, S.M (Author), Chay, S.Y (Author), Ghanisma, S.B.M (Author), Hamid, A.A (Author), Hussein, F.A (Author), Ibadullah, W.Z.W (Author), Saari, N. (Author), Zarei, M. (Author)
Format: Article
Language:English
Published: Elsevier Inc., 2020
Subjects:
angiotensin-converting enzyme (ACE) inhibition
Angiotensin-Converting Enzyme Inhibitors
animal
Animals
antihypertensive agent
Antihypertensive Agents
bioactive peptide
blood pressure
Blood Pressure
chemistry
dipeptidyl carboxypeptidase inhibitor
drug effect
female
Female
hydrolysis
Hydrolysis
male
Male
metabolism
peptide
Peptides
protein hydrolysate
Protein Hydrolysates
rat
rat study
Rats
Rats, Inbred SHR
Rats, Inbred WKY
spontaneously hypertensive rat
subtilisin
Subtilisins
whey protein
whey protein concentrate
Whey Proteins
Wistar Kyoto rat
Online Access:View Fulltext in Publisher
View in Scopus

Internet

View Fulltext in Publisher
View in Scopus

Similar Items